Diabetes最新文献

{"title":"2077-P: Exposure to Maternal Overnutrition In Utero and Offspring Abdominal and Hepatic Fat Trajectories","authors":"CATHERINE C. COHEN, ERIN K. ENGLUND, JASON GILES, DEBORAH GLUECK, MEGAN KELSEY, DANA DABELEA","doi":"10.2337/db26-2077-p","DOIUrl":"https://doi.org/10.2337/db26-2077-p","url":null,"abstract":"Introduction and Objective: The impact of early life exposure to overnutrition on metabolically adverse body fat distribution patterns in childhood is under-studied. Our objective was to examine associations between markers of maternal overnutrition during pregnancy (maternal pre-pregnancy BMI [ppBMI], fasting glucose [FG] and triglycerides [TG] levels) with offspring abdominal and hepatic fat trajectories. Methods: Data were from 433 mother-child pairs in the Colorado Healthy Start Study, a longitudinal pre-birth cohort. Abdominal visceral and subcutaneous adipose tissue (VAT and SAT) areas and hepatic fat fraction (HF) were assessed by MRI in early childhood (~5 y), mid childhood (~9 y), and adolescence (~12 y). Linear mixed models were used to examine associations of maternal ppBMI, FG, and TG during pregnancy with differences in offspring adiposity trajectories. Results: Mean values for all adiposity measures increased from early childhood (HF: 1.9%, SAT: 47 cm2, VAT: 12 cm2) through adolescence (HF: 2.3%, SAT: 150 cm2, VAT: 29 cm2). Maternal ppBMI and FG were associated with higher offspring SAT, VAT, and HF at nearly all visits in childhood and adolescence, with the strongest effect sizes in adolescence; whereas, maternal TG was primarily associated with higher offspring HF, with the strongest effect size in early childhood (Table 1). Conclusion: Overnutrition in utero may be an important risk factor for adverse adiposity outcomes in offspring. Disclosure C.C. Cohen: None. E.K. Englund: None. J. Giles: None. D. Glueck: None. M. Kelsey: Research Support; Current; Rhythm Pharmaceuticals, Inc. D. Dabelea: None. Funding National Institutes of Health (K99DK136503, R01DK133235)","PeriodicalId":11376,"journal":{"name":"Diabetes","volume":"5 1","pages":""},"PeriodicalIF":7.7,"publicationDate":"2026-06-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148286381","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"2097-P: Age at Type 1 Diabetes Diagnosis Is an Independent Risk Factor from HLA for Development of Type 1 Diabetes in First-Degree Relatives","authors":"GREGORY POWER, MICHAEL TANSEY, CATHERINA PINNARO, ANDREW NORRIS","doi":"10.2337/db26-2097-p","DOIUrl":"https://doi.org/10.2337/db26-2097-p","url":null,"abstract":"Introduction and Objective: HLA genotype is the strongest genetic predictor of T1D risk. Highest risk HLA genotypes include DR3/DR4-DQB1*03:02 (DR3 and DR4). Islet autoantibodies are a marker of additional risk. This study aims to assess whether inclusion of age of onset for T1D in first-degree relatives (FDR) improves model prediction of risk for development of T1D beyond HLA and autoantibody status. Methods: This study analyzed cohort data obtained from the TrialNet Pathway to Prevention Study. Data was collected between March 14, 2004, and July 31, 2025. This study included 3,989 individuals with a single FDR with T1D who had available HLA genotypes and islet autoantibodies. A logistic regression to predict development of T1D was created utilizing DR3 and DR4 status, number of islet autoantibodies positive at initial screen, type of FDR with T1D, and age group at which FDR was diagnosed with T1D. Statistical analyses were performed using R version 4.4.2. Results: Even after controlling for the other variables described above, FDR onset age group remained an independent and statistically significant predictor for development of T1D (Likelihood-Ratio Chi-square = 32.32 (p < 0.001)). Individuals with an FDR diagnosed prior to age 5 (n = 1033) showed significantly increased odds to develop T1D compared to individuals with an FDR diagnosed between ages 6 and 10 (n = 1306, OR [95% CI] = 1.27 [1.05 - 1.53]), between ages 11 and 18 (n = 1052, OR = 1.53 [1.26 - 1.89]), or after age 18 (n = 598, OR = 2.21 [1.66 - 2.96]). Conclusion: Age of diagnosis at time of T1D in FDRs is an independent risk factor from HLA genotype and autoantibodies for development of T1D. Individuals with an FDR diagnosed prior to age 5 have significantly increased risk for development of T1D compared to individuals with an FDR diagnosed in older age groups. Disclosure G. Power: None. M. Tansey: Research Support; Current; Novo Nordisk, Diamyd, Provention Bio, Inc. Research Support; Ended; MannKind Corporation. Research Support; Current; Lumos Pharma, Inc., Ascendis Pharma A/S, Diurnal Ltd, Acadia Pharmaceuticals Inc., Eli Lilly and Company, BioMarin Pharmaceutical Inc. C. Pinnaro: None. A. Norris: None.","PeriodicalId":11376,"journal":{"name":"Diabetes","volume":"123 1","pages":""},"PeriodicalIF":7.7,"publicationDate":"2026-06-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148286391","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"2092-P: Early Prevalence Shift from Type 1 towards Type 2 Diabetes across Adolescence and Young Adulthood with Marked Racial and Ethnic Differences: The PAPAYA Study","authors":"SHYLAJA SRINIVASAN, ANDREW KARTER, JENNIFER Y. LIU, CINDY J. HUANG, JULIA ACKER, SAHER DAREDIA, JULIANNA DEARDORFF, SONYA NEGRIFF, ALKA KANAYA, AI KUBO","doi":"10.2337/db26-2092-p","DOIUrl":"https://doi.org/10.2337/db26-2092-p","url":null,"abstract":"Introduction and Objective: The growing burden of type 2 diabetes (T2D) in adolescents and young adults (AYAs) has highlighted changing diabetes patterns at younger ages. We determined changes in prevalence of type 1 diabetes (T1D) and T2D across the adolescent and young adult ages and examined differences across racial and ethnic groups. Methods: We analyzed 2024 electronic health record data from 783,801 AYAs aged 10-30 years with prevalent diabetes from Kaiser Permanente Northern California as part of the Predictors of Adverse Cardiometabolic Problems in Adolescents and Young Adults (PAPAYA) Study. Diabetes type was classified using a validated algorithm. We calculated the proportion of T1D and T2D cases by age and race/ethnicity across four age categories (10-15, 16-20, 21-25 and 26-30). Results: The prevalence of T1D and T2D among KPNC members aged 10-30 years was 4.32 and 6.56/1,000 respectively. Overall, T1D was more common than T2D (3.28 vs 1.04/1000) in early adolescence, but T2D increased steadily with age, becoming the more common type by ages 21-25 (T1D: 6.67 vs T2D: 4.97/1000) (Fig 1a). Earlier T2D predominance was evident in all non-White groups (Fig 1b-1i). Conclusion: In this diverse, real-world cohort, we observed an early and progressive relative rise in T2D that differed markedly by race and ethnicity. These findings underscore the need for screening and clinical strategies that reflect this shifting epidemiology. Disclosure S. Srinivasan: Research Support; Current; Abbott, Eli Lilly and Company. A. Karter: Research Support; Current; Dexcom, Inc. J.Y. Liu: None. C.J. Huang: None. J. Acker: None. S. Daredia: None. J. Deardorff: None. S. Negriff: None. A. Kanaya: None. A. Kubo: None. Funding National Institutes of Health (R01DK139116)","PeriodicalId":11376,"journal":{"name":"Diabetes","volume":"1 1","pages":""},"PeriodicalIF":7.7,"publicationDate":"2026-06-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148286394","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"2065-P: Trends in Metabolic Medication Use among Youth Receiving Antipsychotics, 2016–2024","authors":"OZI IYALOMHE, ALEJANDRO AMILL-ROSARIO, ROZALINA MCCOY, SUSAN DOSREIS","doi":"10.2337/db26-2065-p","DOIUrl":"https://doi.org/10.2337/db26-2065-p","url":null,"abstract":"Introduction and Objective: Youth treated with antipsychotic medications have a 2-3-fold higher risk of new-onset diabetes than youth who do not receive an antipsychotic. Metformin is the standard of care, but this may be replaced by newer FDA-approved treatments, such as glucagon-like peptide-1 receptor agonists (GLP-1RA) and sodium-glucose cotransporter-2 inhibitors (SGLT2i). We aimed to examine trends in metabolic medications - metformin, GLP-1RA, and SGLT2i - among US youth receiving antipsychotics. Methods: Using the IQVIA PharMetrics® Plus for Academics claims data 2016-2024, we examined annual cross-sectional trends in metformin, GLP-1RA, and SGLT2i in youth 5-17 years-old treated with an antipsychotic. We estimated the quarterly prevalence over the entire study period, overall and stratified by age (5-11, 12-17 years) and sex. Results: The 61,792 antipsychotic-treated youth were male (57%) and 5-11 years-old (69%). Metabolic medication use increased from 2.4% (2016) to 4.3% (2024). GLP-1RA use reached 0.8% in the most recent quarter. Less than 0.05% used SGLT-2i. Metformin is the most prevalent overall, and for females and 12-17-year-olds. Conclusion: Metabolic medication use in antipsychotic-treated youth remains low but trending upward with recent uptake of GLP-1RA among 12-17 year-old females. Disclosure O. Iyalomhe: None. A. Amill-Rosario: None. R. McCoy: None. S. dosReis: None.","PeriodicalId":11376,"journal":{"name":"Diabetes","volume":"157 1","pages":""},"PeriodicalIF":7.7,"publicationDate":"2026-06-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148286815","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"2069-P: Risk of Suicidal Ideation and Behaviors, Depression, and Anxiety with GLP-1 Receptor Agonist Use in Children and Adolescents: A Target Trial Emulation Study","authors":"PAREETA KOTECHA, YAO AN LEE, ANGELINA BERNIER, SARAH WESTEN, STEVEN M. SMITH, PENGYUE ZHANG, TAMARA S. HANNON, JIANG BIAN, SERENA JINGCHUAN GUO","doi":"10.2337/db26-2069-p","DOIUrl":"https://doi.org/10.2337/db26-2069-p","url":null,"abstract":"Introduction and Objective: Rising rates of obesity and youth-onset type 2 diabetes (YT2D) among children and adolescents have increased GLP-1 receptor agonist (GLP-1 RA) use, raising concerns about potential effects on suicidal ideation/behaviors (SI/SB), depression, and anxiety. Therefore, we aimed to assess associations between GLP-1 RA use for obesity or YT2D and risk of SI/SB, depression, and anxiety in children and adolescents. Methods: This retrospective cohort study used electronic health record data from the OneFlorida+ Clinical Research Network from January 1, 2020, through January 31, 2024, using a target trial emulation approach with a prevalent-new user design. The study included children and adolescents aged 6 to younger than 18 years with obesity or YT2D and no prior history of the outcomes of interest at baseline. New users of GLP-1 RAs were compared with prevalent users of metformin. Confounding was addressed using stabilized inverse probability of treatment weighting. Weighted Cox proportional hazards models were used to estimate hazard ratios and risk differences (RDs) for suicidal ideation or behavior, anxiety, and depression. RDs were reported per 1,000 person-years, with 95% confidence intervals. Results: The study included 2,010, 1,774, and 1,764 patients for SI/SB, depression, and anxiety, respectively. The mean age was ~14.2 years, ~61% were female, with up to 4 years of follow-up, across cohorts. Compared to prevalent metformin users, GLP-1 RA users had a lower incidence and risk of SI/SB (RD: -10.45, -14.54 to -6.36; HR: 0.11, 0.02 to 0.86) and depression (RD: -25.64, -34.90 to -16.39; HR: 0.37, 0.17 to 0.78). There was no difference in anxiety risk between the two groups (RD: 5.95, -7.10 to 19.01; HR: 1.13, 0.69 to 1.84). Conclusion: GLP-1 RA use may reduce the risks of SI/SB and depression among children and adolescents with obesity or YT2D; no significant association was found for anxiety. Long-term surveillance is needed in this vulnerable population. Disclosure P. Kotecha: Employee; Ended; Merck & Co., Inc. Y. Lee: None. A. Bernier: Research Support; Current; Lilly. S. Westen: None. S.M. Smith: None. P. Zhang: None. T.S. Hannon: None. J. Bian: None. S. Guo: None. Funding NIH/NIDDK (R01DK133465)","PeriodicalId":11376,"journal":{"name":"Diabetes","volume":"60 1","pages":""},"PeriodicalIF":7.7,"publicationDate":"2026-06-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148286816","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"2068-P: Effect of Phentermine/Topiramate on Insulin Sensitivity and Beta-Cell Function in Adolescents with Youth-Onset Type 2 Diabetes and Obesity","authors":"MEGAN O. BENSIGNOR, REBECCA FREESE, AARON S. KELLY, KYLE RUDSER, SILVA ARSLANIAN","doi":"10.2337/db26-2068-p","DOIUrl":"https://doi.org/10.2337/db26-2068-p","url":null,"abstract":"Introduction and Objective: First-line treatment for youth-onset type 2 diabetes (Y-T2D) does not improve insulin sensitivity (IS) and β-cell function (BCF). This study aims to evaluate phentermine/topiramate (PHEN/TPM) versus placebo on IS and BCF for adolescents with Y-T2D. Methods: A 24-week trial in adolescents, 12-20 years, with Y-T2D was conducted. Participants were randomized 1:1 to placebo or PHEN/TPM, an oral obesity medication. PHEN/TPM was increased to 15 mg/92 mg after 8 weeks. Participants treated with metformin ± insulin prior to enrollment remained on these medications. A 2 hour, 75-gram OGTT was performed at baseline and 24 weeks with assessment of insulinogenic index (IGI; ΔInsulin30/Δglucose30), IS (1/fasting insulin), and BCF relative to IS (oral deposition index [oDI]). Linear regression estimated the treatment effect on IS and BCF adjusted for baseline values. Results: Thirteen participants (mean age: 15.5 ± 2.07 years, 38.5% female) were randomized. Baseline HbA1c was 8.1% ± 1.7 with 53.8% of participants on insulin therapy. The estimated treatment difference (ETD) in oDI, insulin sensitivity and IGI were not statistically significant (Table 1). Conclusion: PHEN/TPM was not associated with significant changes in IS or BCF in adolescents with T2D compared to placebo. A larger sample size may be needed for significant improvements to surface in IS and BCF consequent to adiposity reductions with PHEN/TPM. Disclosure M.O. Bensignor: Research Support; Current; Dexcom, Inc., Vivus Inc. R. Freese: None. A.S. Kelly: Advisory Panel; Current; Boehringer Ingelheim International GmbH, Eli Lilly and Company, Novo Nordisk. Research Support; Current; Vivus, Novo Nordisk. K. Rudser: None. S. Arslanian: None. Funding National Institutes of Health NIDDK K23DK129721","PeriodicalId":11376,"journal":{"name":"Diabetes","volume":"28 1","pages":""},"PeriodicalIF":7.7,"publicationDate":"2026-06-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148286378","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"2116-P: The Exocrine Pancreas in the Pathway to Type 1 Diabetes: Size, Function, and Progression","authors":"BRITTANY S. BRUGGEMAN, KAYLA MORNEAULT-GILL, JOSEPH R. GRAJO, MICHAEL GUYOT, SARAH PEELING, MICHAEL J. HALLER, MARTHA L. CAMPBELL-THOMPSON","doi":"10.2337/db26-2116-p","DOIUrl":"https://doi.org/10.2337/db26-2116-p","url":null,"abstract":"Introduction and Objective: Exocrine pancreas dysfunction and atrophy are characteristic of presymptomatic T1D. We sought to determine whether pancreas size by MRI or fecal elastase (FE-1) predicts T1D risk and whether a decline over time is predictive of progression. Methods: T1D islet autoantibody negative relatives (Aab-; n=60), single (sAab+; n=29) and multiple autoantibody positives (mAab+; n=46) aged 8-45 participating in TrialNet Pathway to Prevention were recruited across seven centers in the US and Australia. Relative pancreas volume by MRI (RPV; calculated as volume/BMI; n=135) and FE-1 (n=85) were measured at baseline and one year. A linear model with age and sex as covariates estimated an intercept and slopes across the groups. Nonparametric tests were used to correlate FE-1 with RPV, estimate differences in baseline FE-1, and document trajectories among euglycemic vs dysglycemic participants. Results: Aab-, sAab+, and mAab+ groups had sequentially smaller RPV measured at baseline (p=0.009). However, there was no observable decrease or differences in RPV slope after one year among the groups (p=0.88). FE-1 was not correlated with RPV (rs=0.14, p=0.22). Differences were observed in FE-1 at baseline in euglycemic vs dysglycemic participants (median 2311 vs 1350 mcg/g, p=0.009). Progressors from euglycemia to dysglycemia at one year (n=10) had a downward FE-1 trajectory vs non-progressors (n=20) (median one year value 65% vs 111% of baseline, p=0.02), largely due to a higher baseline FE-1 in progressors vs nonprogressors (FE-1 median 2230 vs 1623 mcg/g, p=0.01). Conclusion: RPV is sequentially smaller in Aab-, sAab+, and mAab+ groups, however, in our study no differences were observed in trajectory over time. Additional analyses incorporating glycemic status are expected. Baseline differences and differences in FE-1 trajectory were apparent in euglycemic vs dysglycemic participants and in euglycemic participants progressing to dysglycemia. Further study is warranted to determine the utility of these exocrine biomarkers as predictors of T1D progression. Disclosure B.S. Bruggeman: Research Support; Current; GentiBio. K. Morneault-Gill: None. J.R. Grajo: None. M. Guyot: None. S. Peeling: None. M.J. Haller: Advisory Panel; Current; MannKind Corporation, Sanofi, SAB Biotherapeutics, Inc. M.L. Campbell-Thompson: None. Funding National Institutes of Health (R01DK123329, K23DK131363)","PeriodicalId":11376,"journal":{"name":"Diabetes","volume":"8 1","pages":""},"PeriodicalIF":7.7,"publicationDate":"2026-06-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148286811","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"2060-P: Improving CGM Prescribing through Targeted Outreach and Physician Support Tools for Type 2 Diabetes","authors":"JOSEPH GINTY, LORI J. LAMMERT, HEATHER DONNELLY, ALEXANDRA HINTZ, SARAH MILLER-BRANAM, AMBER HEALY, SARAH E. ADKINS, ELIZABETH A. BEVERLY","doi":"10.2337/db26-2060-p","DOIUrl":"https://doi.org/10.2337/db26-2060-p","url":null,"abstract":"Introduction and Objective: Continuous Glucose Monitoring (CGM) is associated with improved glycemic management and overall outcomes among people with diabetes. We tested whether physician education, workflow tools, and patient outreach would increase CGM prescribing and improve A1c outcomes. Methods: Control charts using electronic health record data tracked CGM prescribing and the percentage of adults with an A1c >= 9% with a diagnosis of type 2 diabetes who were seen during the prior two months. Interventions were tracked using PDSA tracking sheets. Results: One upward shift in CGM prescribing for adults with A1c >= 9 was observed within six months, increasing the mean from 21.7% to 39.3%. During the same period, the mean percentage of adults with A1c >= 9 initially rose from 18% to 23.4% then decreased to 19.3%. Conclusion: Patient outreach combined with provider education and workflow tools increased CGM prescribing. Glycemic outcomes may lag as more high-risk people with diabetes engage. Disclosure J. Ginty: None. L.J. Lammert: None. H. Donnelly: None. A. Hintz: None. S. Miller-Branam: None. A. Healy: Consultant; Ended; Novo Nordisk. Speaker's Bureau; Current; Sanofi. S.E. Adkins: None. E.A. Beverly: None. Funding Ohio Department of Medicaid (G-2627-05-0009-ODM/202619)","PeriodicalId":11376,"journal":{"name":"Diabetes","volume":"27 1","pages":""},"PeriodicalIF":7.7,"publicationDate":"2026-06-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148286822","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"2115-P: Change in Bone Mineral Density (BMD) over 12 Months in Youth with Type 1 Diabetes (T1D)","authors":"NESSA TANTIVIT, LISA VOLKENING, LIANE J. TINSLEY, LORI M. LAFFEL","doi":"10.2337/db26-2115-p","DOIUrl":"https://doi.org/10.2337/db26-2115-p","url":null,"abstract":"Introduction and Objective: Previous reports show lower BMD in youth with T1D compared with pediatric reference data, yet longitudinal data on BMD remain limited. This study evaluated BMD changes over 12 months and factors affecting BMD change. Methods: Youth (N=115) with T1D aged 8-17 yrs underwent total body less head BMD assessment at 0 and 12 months. Anthropometrics, pubertal status, T1D-related variables, 25-hydroxyvitamin D (25OHD), and weight-bearing activity were collected at both time points. BMD z-scores were categorized as decreased, unchanged, or increased (±0.1 cutoff). Results: Mean baseline age was 12.9±2.5 yrs, T1D duration 6.1±3.2 yrs. Baseline and 12-month BMD z-scores were -0.29±1.03 and -0.13±1.06; BMI z-scores 0.67±0.82 and 0.67±0.83; A1c 8.1±1.1% and 8.4±1.1%; time in range (TIR) 48.6±16.8% and 48.4±17.1%; 25OHD 29.1±8.5 and 30.8±10.8 ng/mL; and energy expenditure from high-impact weight-bearing activities (EE) 207.0±363.7 and 157.2±281.2 kcal/day. Over 12 months, 63 youth (55%) had increased BMD z-score, 19 (17%) had no change, and 33 (29%) had decreased BMD z-score. Age differed across BMD change groups (11.8, 12.8, and 13.5 yrs for decreased, no change, and increased, respectively; p = .004). BMI z-score differed across BMD change groups at baseline (0.41, 0.54, and 0.84, p = .04) and 12 months (0.44, 0.61, and 0.87; p = .02), for decreased, no change, and increased, respectively. Pubertal status differed across BMD change groups (p = .003); decreased BMD group had higher proportion of pre-pubertal youth versus no-change group (58% vs 26%, p = .01) and increased group (58% vs 22%, p = .001). Higher EE was associated with increasing BMD z-score (p = .05). There were no associations of change in BMD z-score with A1c, TIR, or 25OHD. Conclusion: Over 12 months, increase change in BMD z-score in youth with T1D were associated with older age, higher BMI z-score, more advanced pubertal status, and higher EE from high-impact weight-bearing activity. The absence of glycemic and 25OHD effects on BMD warrants further study with longer follow-up. Disclosure N. Tantivit: None. L. Volkening: None. L.J. Tinsley: None. L.M. Laffel: Other - Travel support for scientific presentations; Ended; Boehringer Ingelheim International GmbH. Other - DSMB Chair; Ended; Janssen Pharmaceuticals, Inc. Consultant; Current; Dexcom, Inc. Advisory Panel; Current; Medtronic, Sequel, Tandem Diabetes Care, Inc. Consultant; Current; Roche Diabetes Care, Sinocare. Advisory Panel; Ended; Sanofi. Advisory Panel; Current; MannKind Corporation. Funding National Institutes of Health (5T32DK007260-47)","PeriodicalId":11376,"journal":{"name":"Diabetes","volume":"17 1","pages":""},"PeriodicalIF":7.7,"publicationDate":"2026-06-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148286838","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"2066-P: Exploring the Association between Cord Blood DNA Methylation and Childhood Adiposity: Insights from an Epigenome-Wide Association Study in the HAPO Follow-Up Study","authors":"SEAN DELACEY, YUEMING LIU, WILLIAM LOWE, MARIE-FRANCE HIVERT, DENISE SCHOLTENS, JAMI JOSEFSON","doi":"10.2337/db26-2066-p","DOIUrl":"https://doi.org/10.2337/db26-2066-p","url":null,"abstract":"Introduction and Objective: Intrauterine exposure to gestational hyperglycemia is associated with greater offspring adiposity, but the mechanisms are unclear. A potential mechanism is early life DNA methylation (DNAm). We hypothesized that differential cord blood (CB) DNAm is associated with peripubertal adiposity. Methods: Using a multinational longitudinal birth cohort, we conducted a discovery epigenome wide association study (EWAS) using the Illumina 850K beadchip. CB DNAm (as M-values) were the predictor; outcomes included childhood serum leptin (n=882) and direct adiposity measures at 10-14 years of age (mean 11.5): BMI z-score, sum of skinfolds (SSF), waist circumference (WC), and air displacement plethysmography bodyfat%, n=2597-2937. Benjamini-Hochberg FDR-adjusted p<0.05 defined statistical significance. Regression models adjusted for maternal and child covariates including maternal glucose and BMI, cell types, and ancestry. Results: Eleven CpG sites were significantly associated with WC and one with serum leptin (Table 1). A CpG site near AHAK2, a gene involved in body fat regulation, was associated with WC. There were no associations between CB DNAm and BMI z-score, SSF, or bodyfat%. Conclusion: CB DNAm marks on several genes, including AHNAK2, are associated with WC and serum leptin levels 10-14 years later. Disclosure S. DeLacey: None. Y. Liu: None. W. Lowe: None. M. Hivert: None. D. Scholtens: None. J. Josefson: None. Funding Ruth L. Kirschstein National Research Service Award T32 (DK007169), National Institutes of Health (R01DK118403), National Institutes of Health (UL2TR001422).","PeriodicalId":11376,"journal":{"name":"Diabetes","volume":"16 1","pages":""},"PeriodicalIF":7.7,"publicationDate":"2026-06-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148286848","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}